Skip to content
DraconiticResearch
Search Sources API
220,595 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY 4.0Journal of Psychopharmacology (Oxford, England)

Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977

  • Torsten Passie1,2
  • Michiel van Elk3
  1. 1Hannover Medical School, Germany
  2. 2Dr. Senckenberg Institute for History and Ethics of Medicine, Frankfurt am Main, Germany
  3. 3Cognitive Psychology Unit, Institute of Psychology, Leiden University, The Netherlands
Read full textDOICite

Abstract

Common wisdom in the psychedelic literature suggests that early controlled trials of psychedelic therapy were methodologically flawed. In this review we challenge this view and discuss 11 controlled studies that were conducted in the United States and Canada between 1965 and 1977 to evaluate psychedelic (peak) therapy for individuals suffering from alcohol and opioid use disorder and psychoneuroses. We provide a narrative review of the designs, methods, settings, treatment issues and results and show that these studies already adhered quite well to the regulatory and evidentiary standards of their time. These early psychedelic trials tried to effectively address common methodological problems that still threaten the validity of contemporary psychedelic clinical trials (e.g., regarding blinding and active control conditions). Our review indicates that despite a significant heterogeneity in the methods and research designs, most early controlled studies converge on the same conclusion: there are no durable improvements in the condition of patients treated with psychedelic therapy beyond a few weeks. We discuss implications for contemporary psychedelic science in terms of (a) patient selection (i.e., better prospects for non-chronic conditions), (b) the problems with a single-sided focus on mystical experiences as the primary mechanism of action, (c) the positive afterglow as a therapeutic window of opportunity and (d) the need for a strong psychotherapeutic framework to induce sustained therapeutic effects.

Related

  1. Psychedelic-assisted therapy research for people with HIV
    Nelson Vergel, Parya Saberi
    The lancet. HIVPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  2. Cost-effectiveness of adjunctive hyperbaric oxygen therapy for fibromyalgia: an economic evaluation alongside a single-centre randomised controlled trial in Brazil
    José da Mota Neto, Viviane Angelina De Souza, Pedro Henrique De Oliveira Cabral +3
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textPsychiatry & mental healthCrossref
  3. Letter: Reconsidering Scopolamine as a Psychedelic Adjunct in Exposure-Based Therapy: Cholinergic Modulation and Fear Extinction in Social Anxiety Disorder
    Alexander Bystritsky, Andrew A.E.D. Bishay, Norman M. Spivak +4
    Psychedelic MedicinePeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  4. Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application
    Nima Veiseh, Francesco Kment, Victor Acero +10
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  5. Aspirational autonomy and psychedelic-assisted therapy in advanced cancer: ethical lessons from clinical cases.
    Keenan Wills Davis, Michelle C Bach, JoEllen Schimmels +1
    The oncologistPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{passie2026psychedelic,
  title = {{Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977}},
  author = {Torsten Passie and Michiel van Elk},
  journal = {Journal of Psychopharmacology (Oxford, England)},
  year = {2026},
  month = sep,
  doi = {10.1177/02698811261478606},
  url = {https://doi.org/10.1177/02698811261478606},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977
AU  - Torsten Passie
AU  - Michiel van Elk
PY  - 2026
DA  - 2026/09/07
JO  - Journal of Psychopharmacology (Oxford, England)
DO  - 10.1177/02698811261478606
UR  - https://doi.org/10.1177/02698811261478606
AB  - Common wisdom in the psychedelic literature suggests that early controlled trials of psychedelic therapy were methodologically flawed. In this review we challenge this view and discuss 11 controlled studies that were conducted in the United States and Canada between 1965 and 1977 to evaluate psychedelic (peak) therapy for individuals suffering from alcohol and opioid use disorder and psychoneuroses. We provide a narrative review of the designs, methods, settings, treatment issues and results and show that these studies already adhered quite well to the regulatory and evidentiary standards of their time. These early psychedelic trials tried to effectively address common methodological problems that still threaten the validity of contemporary psychedelic clinical trials (e.g., regarding blinding and active control conditions). Our review indicates that despite a significant heterogeneity in the methods and research designs, most early controlled studies converge on the same conclusion: there are no durable improvements in the condition of patients treated with psychedelic therapy beyond a few weeks. We discuss implications for contemporary psychedelic science in terms of (a) patient selection (i.e., better prospects for non-chronic conditions), (b) the problems with a single-sided focus on mystical experiences as the primary mechanism of action, (c) the positive afterglow as a therapeutic window of opportunity and (d) the need for a strong psychotherapeutic framework to induce sustained therapeutic effects.
SN  - 0269-8811
SN  - 1461-7285
ER  -